The Second Affiliated Hospital, Zhejiang University School of Medicine
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Zhiying
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed
3
176
RoW
PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution
Tasly GeneNet Pharmaceuticals Co., Ltd
Charcot-Marie-Tooth Type 1A
03/24
03/24
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Recruiting
2/3
132
RoW
B001, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Neuromyelitis Optica Spectrum Disorders
10/27
02/29
NCT06556394: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Recruiting
1
32
RoW
RAG-17, Placebo
Ractigen Therapeutics.
Amyotrophic Lateral Sclerosis
02/26
04/26
Xiang, Ying
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT04272151: Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Recruiting
1/2
40
RoW
BCMA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell
12/23
07/24
NCT04272125: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1/2
40
RoW
CD123 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
12/23
07/24
NCT04271800: Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Recruiting
1/2
40
RoW
CD19 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
12/23
07/24
NCT04648475: Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Recruiting
1/2
40
RoW
CD19 and CD22 targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Leukemia, B-cell, Lymphoma, B-Cell
12/23
07/24
Ye, Weidi
No trials found

Download Options